ACRX · Acelrx Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | $2.59M | $3.75M | $6.03M |
| Gross Profit | - | - | - | - | - | - |
| R&D | $6.03M | $6.72M | $5.55M | $5.19M | $4.09M | $4.02M |
| SG&A | $7.48M | $8.53M | $11.99M | $25.67M | $30.93M | $36.33M |
| Total Operating Expenses | $13.51M | $15.25M | $17.54M | $38.40M | $38.78M | $46.38M |
| D&A | - | $0 | $311.0K | $1.65M | $1.97M | $1.85M |
| Operating Income | ($13.48M) | ($15.25M) | ($16.89M) | ($36.63M) | ($35.97M) | ($40.96M) |
| Interest Expense | - | $0 | $134.0K | $1.15M | $2.29M | $3.31M |
| Income Tax | $0 | $0 | $0 | $13.0K | $5.0K | $4.0K |
| Net Income | ($14.29M) | ($13.00M) | ($18.40M) | $47.76M | ($35.10M) | ($40.38M) |
| EPS - Basic | ($0.34) | ($0.50) | ($1.29) | ($5.86) | - | - |
| EPS - Diluted | - | - | ($1.29) | ($5.86) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.89M | $8.86M | $5.72M | $15.28M | $12.66M | $27.27M |
| Accounts Receivable | - | - | - | $309.0K | $160.0K | $635.0K |
| Inventory | - | - | - | $1.18M | $1.11M | $1.63M |
| Accounts Payable | $544.0K | $670.0K | $1.34M | $2.04M | $2.12M | $2.74M |
| Current Assets | $20.90M | $9.42M | $11.56M | $24.57M | $55.49M | $46.83M |
| Total Assets | $29.72M | $18.24M | $20.39M | $47.49M | $77.89M | $66.30M |
| Current Liabilities | $3.81M | $2.65M | $4.51M | $13.77M | $18.51M | $17.64M |
| Long-term Debt | - | - | - | $0 | $5.01M | $13.14M |
| Total Liabilities | $12.68M | $10.23M | $6.29M | $25.67M | $113.79M | $122.05M |
| Stockholders' Equity | $17.04M | $8.00M | $14.11M | $21.81M | ($35.89M) | ($55.75M) |
| Retained Earnings | ($471.52M) | ($457.23M) | ($444.23M) | ($425.83M) | ($473.58M) | ($438.49M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.36M) | ($12.68M) | ($17.49M) | ($28.33M) | ($30.00M) | ($38.51M) |
| Investing Cash Flow | ($14.35M) | $3.78M | ($528.0K) | $36.45M | ($26.12M) | $34.14M |
| Financing Cash Flow | $22.74M | $12.04M | $3.47M | ($507.0K) | $41.51M | $16.96M |
| CapEx | - | $0 | $100.0K | $364.0K | $1.83M | $1.85M |
| Free Cash Flow | - | ($12.68M) | ($17.59M) | ($28.70M) | ($31.83M) | ($40.36M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | 0.98 | 0.96 | -0.60 | 0.91 | 1.00 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | 0.0% | - | - |
| Return on assets | -48.1% | -71.3% | -90.2% | 100.6% | -45.1% | -60.9% |
| Return on equity | -83.9% | -162.5% | -130.4% | 218.9% | 97.8% | 72.4% |
| Return on invested capital | - | - | - | -167.9% | - | - |
| Liquidity | ||||||
| Current ratio | 5.49 | 3.56 | 2.56 | 1.78 | 3.00 | 2.66 |
| Quick ratio | 5.49 | 3.56 | 2.56 | 1.70 | 2.94 | 2.56 |
| Cash ratio | 1.55 | 3.35 | 1.27 | 1.11 | 0.68 | 1.55 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | -0.14 | -0.24 |
| Debt / Assets | - | - | - | 0.00 | 0.06 | 0.20 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -126.0x | -31.8x | -15.7x | -12.4x |
| Equity multiplier | 1.74 | 2.28 | 1.45 | 2.18 | -2.17 | -1.19 |
| Liabilities / Assets | 0.43 | 0.56 | 0.31 | 0.54 | 1.46 | 1.84 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | 2.20 | 3.38 | 3.71 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | 166d | 108d | 98d |
| Days payable outstanding | - | - | - | 287d | 206d | 166d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.6% | 9.7% | 53.9% | -1.9% | 12.2% | 24.4% |
| Net income growth (YoY) | -9.9% | 29.3% | - | - | 13.1% | 24.2% |
| EPS growth (YoY) | - | - | 78.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 27.9% | 38.7% | 9.8% | 21.1% | 26.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 112.9% | -43.3% | -35.3% | - | 35.6% | -34.6% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ACELRX PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.